-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $125

Benzinga·04/25/2025 16:11:38
Listen to the news
Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and lowers the price target from $132 to $125.